The Tool Desk
Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Telangana’s GST appellate authority has upheld a demand against Aurobindo Pharma for alleged excess input tax credit (ITC) claimed in FY 2020–21. The disputed total is ₹4,60,28,908, comprising the alleged excess credit, interest and penalty. The company said it planned to challenge the order before the GST Appellate Tribunal (GSTAT), but the available report does not confirm that an appeal was subsequently filed.
What did the GST authority decide?
According to a PTI report published by Moneycontrol on 30 September 2026, the Appellate Joint Commissioner (ST), Malkajgiri Division, Hyderabad, upheld an earlier ruling dated 28 February 2025. The appellate order was passed under the Central GST Act and the Telangana GST Act.
The dispute concerns an alleged difference between the ITC Aurobindo Pharma claimed in its GSTR-3B returns and the figures reflected in GSTR-2A for FY 2020–21. The report describes the issue and outcome only at a summary level; it does not reproduce the appellate order or explain the authority’s detailed reasoning.
How much is the Aurobindo Pharma GST demand?
The reported total is ₹4,60,28,908, based on the company’s regulatory filing as summarized by PTI/Moneycontrol in 2026. The amount is made up of:
#1 Best Overall
| Component | Reported amount |
|---|---|
| Alleged excess ITC to be reversed | ₹2,56,44,999 |
| Interest | ₹1,78,19,409 |
| Penalty | ₹25,64,500 |
| Total disputed amount | ₹4,60,28,908 |
These are case-specific figures reported from the company disclosure; the news report summarizes the filing rather than reproducing it.
Why was the ITC demand upheld?
The report says the original order alleged that Aurobindo Pharma claimed more ITC in GSTR-3B than was reflected in GSTR-2A for FY 2020–21. It does not provide the appellate authority’s legal analysis, the company’s detailed grounds of challenge, or a fuller explanation of how the difference was assessed. The reported account therefore does not establish the merits of either side’s position beyond the authority’s decision to uphold the earlier ruling.
Rank #2
- Ideal for Gifting
- Ideal for a bookworm
- Compact for travelling
Will Aurobindo Pharma appeal?
Aurobindo Pharma received communication of the appellate order on 28 September 2026 and said it planned to challenge the decision before GSTAT. That is a stated intention, not confirmation that an appeal was filed. The available report does not establish a subsequent filing or any later tribunal outcome.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What does the order mean for the company?
Aurobindo Pharma said the order would not have a material impact on its operations or financial performance. This is the company’s assessment as reported by PTI/Moneycontrol; the report provides no independent financial analysis of the potential effect.
Quick Recap
Best Value
- It can be a gift option
- Comes with secure packaging
- Helpful in various ways
Rank #4
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
